|
WO2020210501A1
|
|
Oral pharmaceutical products and methods of use combining testosterone esters with anti-hypertensive agents
|
|
US2020197412A1
|
|
Methods of treating testosterone deficiency
|
|
US2020323880A1
|
|
Methods of treating testosterone deficiency
|
|
US2018333423A1
|
|
Methods of treating testosterone deficiency
|
|
JP2016028087A
|
|
Oral testosterone ester formulations and methods of treating testosterone deficiency comprising the same
|
|
JP2015134803A
|
|
Oral testosterone ester formulations and methods of treating testosterone deficiency comprising the same
|
|
WO2015100406A1
|
|
Use of oral pharmaceutical products combining testosterone esters with hypolipidemic agents
|
|
AU2014265072A1
|
|
Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
|
|
AU2014232911A1
|
|
Methods of treating testosterone deficiency
|
|
NZ602821A
|
|
Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same
|
|
CN103830245A
|
|
Oral testosterone ester formulation and application of same in preparation of drug used for treating testosterone deficiency
|
|
CN103705462A
|
|
Oral testosterone ester preparation and method for treating testosterone deficiency comprising oral testosterone ester preparation
|
|
CN101217963A
|
|
Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
|
